Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

Daniel Keizman, Peng Huang, Mario A. Eisenberger, Roberto Pili, Jenny J. Kim, Emmanuel S. Antonarakis, Hans Hammers, Michael A. Carducci

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: Sunitinib is a standard treatment for metastatic renal cell carcinoma. Angiotensin system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, are widely used in hypertension, kidney disease and heart failure. Data suggests that they may inhibit tumourigenesis. Aims: To study the effect of angiotensin system inhibitors on sunitinib treatment outcome in metastatic renal cell carcinoma. Methods: We performed a retrospective study of an unselected cohort of patients with metastatic renal cell carcinoma who were treated with sunitinib. Patients were divided into angiotensin system inhibitors users (group 1) and non-users (group 2). The effect of angiotensin system inhibitors on objective response, time to disease progression and overall survival, was tested with adjustment for known confounding risk factors through logistic regression model and Cox regression model. Results: Between 2004 and 2010, 127 patients with metastatic renal cell carcinoma were treated with sunitinib, 44 group 1 and 83 group 2. The groups were balanced regarding known clinicopathologic prognostic factors. Objective response was partial response/stable disease 86% versus 72% and progressive disease 14% versus 28% (p = 0.07) in group 1 versus 2, respectively. Median progression free survival was 13 versus 6 months (HR 0.537, p = 0.0055), and median overall survival 30 versus 23 months (HR 0.688, p = 0.21), in favour of group 1. Conclusions: Angiotensin system inhibitors may improve the outcome of sunitinib treatment in metastatic renal cell carcinoma. This should be investigated prospectively, and if validated applied in clinical practise and clinical trials.

Original languageEnglish (US)
Pages (from-to)1955-1961
Number of pages7
JournalEuropean Journal of Cancer
Volume47
Issue number13
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Angiotensins
Renal Cell Carcinoma
Logistic Models
Survival
Angiotensin Receptor Antagonists
Kidney Diseases
Proportional Hazards Models
Angiotensin-Converting Enzyme Inhibitors
Reaction Time
Disease-Free Survival
Renal Insufficiency
Disease Progression
Heart Failure
Retrospective Studies
sunitinib
Clinical Trials
Hypertension

Keywords

  • Angiotensin converting enzyme inhibitors
  • Angiotensin II receptor blockers
  • Metastatic renal cell carcinoma
  • Outcome
  • Sunitinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma : A retrospective examination. / Keizman, Daniel; Huang, Peng; Eisenberger, Mario A.; Pili, Roberto; Kim, Jenny J.; Antonarakis, Emmanuel S.; Hammers, Hans; Carducci, Michael A.

In: European Journal of Cancer, Vol. 47, No. 13, 09.2011, p. 1955-1961.

Research output: Contribution to journalArticle

Keizman, Daniel ; Huang, Peng ; Eisenberger, Mario A. ; Pili, Roberto ; Kim, Jenny J. ; Antonarakis, Emmanuel S. ; Hammers, Hans ; Carducci, Michael A. / Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma : A retrospective examination. In: European Journal of Cancer. 2011 ; Vol. 47, No. 13. pp. 1955-1961.
@article{cd96baf683d44d21a8d3c1989e9749a6,
title = "Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination",
abstract = "Background: Sunitinib is a standard treatment for metastatic renal cell carcinoma. Angiotensin system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, are widely used in hypertension, kidney disease and heart failure. Data suggests that they may inhibit tumourigenesis. Aims: To study the effect of angiotensin system inhibitors on sunitinib treatment outcome in metastatic renal cell carcinoma. Methods: We performed a retrospective study of an unselected cohort of patients with metastatic renal cell carcinoma who were treated with sunitinib. Patients were divided into angiotensin system inhibitors users (group 1) and non-users (group 2). The effect of angiotensin system inhibitors on objective response, time to disease progression and overall survival, was tested with adjustment for known confounding risk factors through logistic regression model and Cox regression model. Results: Between 2004 and 2010, 127 patients with metastatic renal cell carcinoma were treated with sunitinib, 44 group 1 and 83 group 2. The groups were balanced regarding known clinicopathologic prognostic factors. Objective response was partial response/stable disease 86{\%} versus 72{\%} and progressive disease 14{\%} versus 28{\%} (p = 0.07) in group 1 versus 2, respectively. Median progression free survival was 13 versus 6 months (HR 0.537, p = 0.0055), and median overall survival 30 versus 23 months (HR 0.688, p = 0.21), in favour of group 1. Conclusions: Angiotensin system inhibitors may improve the outcome of sunitinib treatment in metastatic renal cell carcinoma. This should be investigated prospectively, and if validated applied in clinical practise and clinical trials.",
keywords = "Angiotensin converting enzyme inhibitors, Angiotensin II receptor blockers, Metastatic renal cell carcinoma, Outcome, Sunitinib",
author = "Daniel Keizman and Peng Huang and Eisenberger, {Mario A.} and Roberto Pili and Kim, {Jenny J.} and Antonarakis, {Emmanuel S.} and Hans Hammers and Carducci, {Michael A.}",
year = "2011",
month = "9",
doi = "10.1016/j.ejca.2011.04.019",
language = "English (US)",
volume = "47",
pages = "1955--1961",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "13",

}

TY - JOUR

T1 - Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma

T2 - A retrospective examination

AU - Keizman, Daniel

AU - Huang, Peng

AU - Eisenberger, Mario A.

AU - Pili, Roberto

AU - Kim, Jenny J.

AU - Antonarakis, Emmanuel S.

AU - Hammers, Hans

AU - Carducci, Michael A.

PY - 2011/9

Y1 - 2011/9

N2 - Background: Sunitinib is a standard treatment for metastatic renal cell carcinoma. Angiotensin system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, are widely used in hypertension, kidney disease and heart failure. Data suggests that they may inhibit tumourigenesis. Aims: To study the effect of angiotensin system inhibitors on sunitinib treatment outcome in metastatic renal cell carcinoma. Methods: We performed a retrospective study of an unselected cohort of patients with metastatic renal cell carcinoma who were treated with sunitinib. Patients were divided into angiotensin system inhibitors users (group 1) and non-users (group 2). The effect of angiotensin system inhibitors on objective response, time to disease progression and overall survival, was tested with adjustment for known confounding risk factors through logistic regression model and Cox regression model. Results: Between 2004 and 2010, 127 patients with metastatic renal cell carcinoma were treated with sunitinib, 44 group 1 and 83 group 2. The groups were balanced regarding known clinicopathologic prognostic factors. Objective response was partial response/stable disease 86% versus 72% and progressive disease 14% versus 28% (p = 0.07) in group 1 versus 2, respectively. Median progression free survival was 13 versus 6 months (HR 0.537, p = 0.0055), and median overall survival 30 versus 23 months (HR 0.688, p = 0.21), in favour of group 1. Conclusions: Angiotensin system inhibitors may improve the outcome of sunitinib treatment in metastatic renal cell carcinoma. This should be investigated prospectively, and if validated applied in clinical practise and clinical trials.

AB - Background: Sunitinib is a standard treatment for metastatic renal cell carcinoma. Angiotensin system inhibitors, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, are widely used in hypertension, kidney disease and heart failure. Data suggests that they may inhibit tumourigenesis. Aims: To study the effect of angiotensin system inhibitors on sunitinib treatment outcome in metastatic renal cell carcinoma. Methods: We performed a retrospective study of an unselected cohort of patients with metastatic renal cell carcinoma who were treated with sunitinib. Patients were divided into angiotensin system inhibitors users (group 1) and non-users (group 2). The effect of angiotensin system inhibitors on objective response, time to disease progression and overall survival, was tested with adjustment for known confounding risk factors through logistic regression model and Cox regression model. Results: Between 2004 and 2010, 127 patients with metastatic renal cell carcinoma were treated with sunitinib, 44 group 1 and 83 group 2. The groups were balanced regarding known clinicopathologic prognostic factors. Objective response was partial response/stable disease 86% versus 72% and progressive disease 14% versus 28% (p = 0.07) in group 1 versus 2, respectively. Median progression free survival was 13 versus 6 months (HR 0.537, p = 0.0055), and median overall survival 30 versus 23 months (HR 0.688, p = 0.21), in favour of group 1. Conclusions: Angiotensin system inhibitors may improve the outcome of sunitinib treatment in metastatic renal cell carcinoma. This should be investigated prospectively, and if validated applied in clinical practise and clinical trials.

KW - Angiotensin converting enzyme inhibitors

KW - Angiotensin II receptor blockers

KW - Metastatic renal cell carcinoma

KW - Outcome

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=80051889719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051889719&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.04.019

DO - 10.1016/j.ejca.2011.04.019

M3 - Article

C2 - 21600760

AN - SCOPUS:80051889719

VL - 47

SP - 1955

EP - 1961

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 13

ER -